Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13733897 | 0.85 | ESR1 (0.47) | SLC6A2SIGMAR1TAAR1CYP1A2CYP3A4 | |
| SCHEMBL6987000 | 0.85 | CNR1 (0.44) | SLC6A2SLC6A4SLC6A3EPHX1SIGMAR1 | |
| SCHEMBL9985184 | 0.85 | CYP19A1 (0.42) | EPHX1CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL6981682 | 0.85 | CYP19A1 (0.45) | SLC6A4SLC6A3EPHX1 | |
| SCHEMBL28382111 | 0.85 | ESR1 (0.47) | SLC6A2SLC6A3SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL8529164 | 0.80 | MEN1 (0.54) | SLC6A4SIGMAR1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL8910215 | 0.78 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3SIGMAR1TAAR1 | |
| SCHEMBL1147908 | 0.76 | ACP3 (0.48) | SLC6A2SLC6A4SLC6A3SIGMAR1ACP3 | |
| SCHEMBL318537 | 0.76 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3EPHX1SIGMAR1 | |
| SCHEMBL1287678 | 0.76 | EPHX1 (0.55) | SLC6A2SLC6A4SLC6A3EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003384-B | Polymer, preparation method and application thereof | 东莞东阳光医疗智能器件研发有限公司 | 2022-02-15 | — | — | CN | claimed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | claimed |
| CN-1440390-A | Substituted diamine derivatives as motilin antagonists | ORTHO MCNEIL PHARM INC (US) | 2003-09-03 | — | — | CN | claimed |
| EP-0740660-A1 | SUBSTITUTED OXAZOLINES | BAYER AG (DE) | 1996-11-06 | — | — | EP | claimed |
| WO-1995019349-A1 | SUBSTITUTED OXAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-20 | — | — | WO | claimed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| US-5149709-A | Treatment of atherosclerosis | SCHERING CORPORATION (US) | 1992-09-22 | — | — | US | claimed |
| US-4939012-A | Semiconductor laser sensitive | BASF AKTIENGESELLSCHAFT (DE) | 1990-07-03 | — | — | US | claimed |
| US-4830951-A | HIGH SENSITIVITY TO SEMICONDUCTOR LASERS | BASF AKTIENGESELLSCHAFT (DE) | 1989-05-16 | — | — | US | claimed |
| EP-0230151-A2 | Cholecystokinin antagonists | BIOMEASURE, INC. (US) | 1987-07-29 | — | — | EP | claimed |
| US-4220649-A | VASODILATORS AND HYPOTENSIVE AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | SLC6A2 449/4885SLC6A4 586/4885SLC6A3 268/4885 |
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | SLC6A2 1809/4885SLC6A4 1504/4885SLC6A3 1100/4885 |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | SLC6A2 4430/4885SLC6A4 4497/4885SLC6A3 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.